RESUMO
In spite of current treatment strategies, myocardial infarction and stroke are still major causes of death worldwide. These events are triggered by damage of an atherosclerotic plaque, resulting in occlusive thrombus formation. Mouse studies have significantly contributed to our understanding of the mechanisms of atherogenesis and of thrombosis following plaque injury, but the extent to which the mouse serves as an accurate model of human disease is open to discussion. In this review, we provide a detailed overview and comparison of the described mouse models for atherothrombosis including their (dis)advantages. Herein guidance is provided on how to select a suitable atherothrombosis model for research questions primarily relevant to the field of thrombosis.
Assuntos
Trombose das Artérias Carótidas/etiologia , Modelos Animais de Doenças , Camundongos , Placa Aterosclerótica , Animais , Aterosclerose/induzido quimicamente , Aterosclerose/genética , Coagulação Sanguínea , Plaquetas/metabolismo , Plaquetas/fisiologia , Trombose das Artérias Carótidas/induzido quimicamente , Trombose das Artérias Carótidas/metabolismo , Cloretos/toxicidade , Dieta Hiperlipídica , Compostos Férricos/toxicidade , Humanos , Ligadura , Camundongos Knockout para ApoE , Placa Aterosclerótica/induzido quimicamente , Placa Aterosclerótica/patologia , Ondas UltrassônicasRESUMO
Tumors arising within the parotid encompass a heterogeneous mix of benign and malignant neoplasms and other tissue growths. The purpose of this study was to determine the association between the location of intraparotid masses and the risk of malignancy. A retrospective cohort study was performed of patients diagnosed with parotid tumors following open tumor excision. The primary predictor variable was the location of the epicenter of the tumor in three-dimensional space, as determined from preoperative imaging. Other variables were patient demographics and clinical parameters. The primary outcome variable was the final histopathologic diagnosis of a benign or malignant process. A χ2 analysis was performed to test for any significant associations between demographic, clinical, and radiographic factors in relation to the outcome, and backwards stepwise logistic regression analysis was used to control for variables. Both increasing age (P = 0.002) and the presence of local pain (P = 0.020) were associated with malignancy. Tumors located anterior to the posterior border of the retromandibular vein had 2.18 times higher odds of malignancy (95% confidence interval 1.13-4.21; P = 0.020). Multivariate regression analysis suggested that patient age, the presence of pain, and tumor location anterosuperiorly and superoinferiorly could all assist in determining the odds of malignancy.
Assuntos
Neoplasias Parotídeas , Humanos , Neoplasias Parotídeas/diagnóstico por imagem , Neoplasias Parotídeas/patologia , Estudos Retrospectivos , Glândula Parótida/patologia , Glândula Parótida/cirurgiaRESUMO
We present outcomes following total joint replacement of the temporomandibular joint (TMJ) in adolescent and young adult patients with juvenile idiopathic arthritis (JIA), and discuss a multidisciplinary treatment model. A retrospective review was performed of patients presenting to the University of North Carolina Oral and Maxillofacial Surgery Service (Chapel Hill, NC) from 2016- 2018 who underwent unilateral or bilateral total replacement of the TMJ for a diagnosis of end-stage joint disease secondary to JIA. Inclusion criteria included diagnosis by a rheumatologist, presentation to our department in adolescence (under 18 years of age), surgical intervention in adolescence or young adulthood (under 25 years of age), and documentation of preoperative and postoperative pain, maximum incisal opening (MIO), and quality of life measures. A database was created and data were then analysed both qualitatively and quantitatively. Five patients met the inclusion criteria. All achieved MIO of more than 35mm with a mean improvement of 24mm, and were able to tolerate a regular diet. All preoperative pain had essentially been eliminated. All patients reported a considerable improvement in quality of life. To our knowledge, this is the first report to document a series of paediatric and young adult patients with JIA who required total replacement of the joint for end-stage joint disease. To our knowledge, it is also the first to describe the use of a collaborative clinic of oral and maxillofacial surgeons, neuroradiologists, dental radiologists, orofacial pain specialists, paediatric rheumatologists, and paediatric nurse practitioners, to care for these patients.
Assuntos
Artrite Juvenil , Transtornos da Articulação Temporomandibular , Adolescente , Adulto , Artrite Juvenil/complicações , Artrite Juvenil/cirurgia , Criança , Humanos , Qualidade de Vida , Estudos Retrospectivos , Articulação Temporomandibular/diagnóstico por imagem , Articulação Temporomandibular/cirurgia , Transtornos da Articulação Temporomandibular/cirurgia , Adulto JovemRESUMO
The in vitro production of blood platelets for transfusion purposes is an important goal in the context of a sustained demand for controlled products free of infectious, immune and inflammatory risks. The aim of this study was to characterize human platelets derived from CD34+ progenitors and to evaluate their hemostatic properties. These cultured platelets exhibited a typical discoid morphology despite an enlarged size and expressed normal levels of the major surface glycoproteins. They aggregated in response to ADP and a thrombin receptor agonist peptide (TRAP). After infusion into NSG mice, cultured and native platelets circulated with a similar 24 h half-life. Notably, the level of circulating cultured platelets remained constant during the first two hours following infusion. During this period of time their size decreased to reach normal values, probably due to their remodeling in the pulmonary circulation, as evidenced by the presence of numerous twisted platelet elements in the lungs. Finally, cultured platelets were capable of limiting blood loss in a bleeding assay performed in thrombocytopenic mice. In conclusion, we show here that cultured platelets derived from human CD34+ cells display the properties required for use in transfusion, opening the way to clinical trials.
Assuntos
Antígenos CD34 , Plaquetas/fisiologia , Hemostasia , Agregação Plaquetária , Transfusão de Plaquetas , Células-Tronco , Difosfato de Adenosina/farmacologia , Animais , Plaquetas/metabolismo , Células Cultivadas , Feminino , Glicoproteínas/metabolismo , Técnicas In Vitro , Camundongos Transgênicos , Fragmentos de Peptídeos/farmacologia , Agregação Plaquetária/efeitos dos fármacosRESUMO
Necrotizing cellulitis, necrotizing fasciitis, and necrotizing myositis are a constellation of severe soft tissue infections characterized by rapid progression, dusky soft tissue changes, and edema and induration expanding beyond the clinical wound edges. The cases of two female patients with type II necrotizing soft tissue infections occurring after routine third molar extraction are reported here. The patients were treated for the infections at the University of North Carolina Hospitals in 2016. Both were previously healthy. Of particular interest, recent inoculation of group A Streptococcus appears to have contributed to the infection in both cases.
Assuntos
Fasciite Necrosante , Infecções dos Tecidos Moles , Feminino , Humanos , Dente SerotinoRESUMO
A systematic review of published articles on ultrasound (US) and magnetic resonance imaging (MRI) of the temporomandibular joint (TMJ) in juvenile idiopathic arthritis (JIA) was performed to answer the question "What is the sensitivity and specificity of US as compared to MRI in diagnosing acute and chronic joint changes in patients with JIA?" The most recent evidence was sought in published articles via a search of the PubMed, Ovid, and Embase databases. Article appraisal was performed by two reviewers. Nineteen articles reporting prospective or ambispective studies comparing US to MRI in TMJ imaging were found. Six of these articles were specific to JIA patients. The heterogeneity of these articles made comparison difficult. Of the acute and chronic changes assessed (disk displacement, joint effusion, bony deformity), only joint effusion was appropriately assessed by multiple authors, with US having a sensitivity of 0-72% and specificity of 70-83% as compared to MRI. There was a paucity of studies specific to JIA, with many studying adult, non-rheumatic patients. This systematic review found that dynamic imaging with high-resolution US improves sensitivity and specificity compared to static, low-resolution US. Additionally, there is evidence to suggest that US imaging following a baseline MRI can increase US sensitivity and specificity and may have a future role in disease surveillance.
Assuntos
Artrite Juvenil/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Transtornos da Articulação Temporomandibular/diagnóstico por imagem , Ultrassonografia/métodos , Criança , HumanosRESUMO
ADP is a key agonist in hemostasis and thrombosis. ADP-induced platelet activation involves the purinergic P2Y(1) receptor, which is responsible for shape change through intracellular calcium mobilization. This process also depends on an unidentified P2 receptor (P2cyc) that leads to adenylyl cyclase inhibition and promotes the completion and amplification of the platelet response. P2Y(1)-null mice were generated to define the role of the P2Y(1) receptor and to determine whether the unidentified P2cyc receptor is distinct from P2Y(1). These mice are viable with no apparent abnormalities affecting their development, survival, reproduction, or the morphology of their platelets, and the platelet count in these animals is identical to that of wild-type mice. However, platelets from P2Y(1)-deficient mice are unable to aggregate in response to usual concentrations of ADP and display impaired aggregation to other agonists, while high concentrations of ADP induce platelet aggregation without shape change. In addition, ADP-induced inhibition of adenylyl cyclase still occurs, demonstrating the existence of an ADP receptor distinct from P2Y(1). P2Y(1)-null mice have no spontaneous bleeding tendency but are resistant to thromboembolism induced by intravenous injection of ADP or collagen and adrenaline. Hence, the P2Y(1) receptor plays an essential role in thrombotic states and represents a potential target for antithrombotic drugs.
Assuntos
Agregação Plaquetária , Receptores Purinérgicos P2/fisiologia , Trombose/prevenção & controle , Difosfato de Adenosina/farmacologia , Animais , Tempo de Sangramento , Feminino , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Ativação Plaquetária , Receptores Purinérgicos P2Y1 , Recombinação GenéticaRESUMO
UNLABELLED: ESSENTIALS: The role of ATP-binding cassette transporter 1 (ABCA1) in platelet functions is poorly characterized. We studied the impact of ABCA1 deficiency on platelet responses in a mouse model and two Tangier patients. ABCA1-deficient platelets exhibit reduced positive feedback loop mechanisms. This reduced reactivity is dependent on external environment and independent of hematopoietic ABCA1. BACKGROUND: The ATP-binding cassette transporter ABCA1 is required for the conversion of apolipoprotein A-1 to high-density lipoprotein (HDL), and its defect causes Tangier disease, a rare disorder characterized by an absence of HDL and accumulation of cholesterol in peripheral tissues. The role of ABCA1 in platelet functions remains poorly characterized. OBJECTIVE: To determine the role of ABCA1 in platelet functions and to clarify controversies concerning its implication in processes as fundamental as platelet phosphatidylserine exposure and control of platelet membrane lipid composition. METHODS AND RESULTS: We studied the impact of ABCA1 deficiency on platelet responses in a mouse model and in two Tangier patients. We show that platelets in ABCA1-deficient mice are slightly larger in size and exhibit aggregation and secretion defects in response to low concentrations of thrombin and collagen. These platelets have normal cholesterol and major phospholipid composition, granule morphology, or calcium-induced phosphatidylserine exposure. Interestingly, ABCA1-deficient platelets display a reduction in positive feedback loop mechanisms, particularly in thromboxane A2 (TXA2) production. Hematopoietic chimera mice demonstrated that defective eicosanoids production, particularly TXA2, was primarily dependent on external environment and not on the hematopoietic ABCA1. Decreased aggregation and production of TXA2 and eicosanoids were also observed in platelets from Tangier patients. CONCLUSIONS: Absence of ABCA1 and low HDL level induce reduction of platelet reactivity by decreasing positive feedback loops, particularly TXA2 production through a hematopoietic ABCA1-independent mechanism.
Assuntos
Transportador 1 de Cassete de Ligação de ATP/deficiência , Plaquetas/metabolismo , Células-Tronco Hematopoéticas/metabolismo , Doença de Tangier/sangue , Transportador 1 de Cassete de Ligação de ATP/sangue , Transportador 1 de Cassete de Ligação de ATP/genética , Animais , Plaquetas/patologia , Tamanho Celular , Modelos Animais de Doenças , Retroalimentação Fisiológica , Feminino , Predisposição Genética para Doença , Transplante de Células-Tronco Hematopoéticas , Hemostasia , Humanos , Lipoproteínas HDL/sangue , Masculino , Camundongos Endogâmicos DBA , Camundongos Knockout , Pessoa de Meia-Idade , Fenótipo , Agregação Plaquetária , Doença de Tangier/genética , Doença de Tangier/patologia , Trombose/sangue , Trombose/genética , Tromboxano A2/metabolismo , Fatores de TempoRESUMO
UNLABELLED: Essentials Role of platelets in immunological transfusion-related acute lung injury (TRALI) is debated. Immunological TRALI was tested in mice exhibiting severe thrombocytopenia or platelet dysfunction. Platelets are required to prevent lung hemorrhage but not edema formation and respiratory distress. Platelets are dispensable for the initiation and development of TRALI. SUMMARY: Background Transfusion-related acute lung injury (TRALI) is a serious transfusion-related complication. Previous conflicting studies have indicated that platelets are either crucial or dispensable for TRALI. Objectives To evaluate the role of platelets in major histocompatibility complex (MHC) I-induced-TRALI. Methods Antibody-mediated TRALI was experimentally induced in mice by lipopolysaccharide priming followed by the administration of an anti-MHC I mAb. Results TRALI was tested in the context of severe thrombocytopenia provoked by the administration of diphtheria toxin (DT) in transgenic iDTR mice selectively expressing DT receptor in megakaryocytes. The pathologic responses occurring within the first 10 min following the injection of the anti-MHC I mAb, i.e. the severity of lung edema and the drop in aortic blood oxygenation, were similar in severely thrombocytopenic DT-iDTR and control mice. At later times, mortality was nevertheless increased in DT-iDTR mice, owing to lung hemorrhages. When less severe thrombocytopenia was induced with an antiplatelet mAb, TRALI started and developed similarly as in control mice, but hemorrhages were absent. Furthermore, when platelet functions were defective because of administration of aspirin or clopidogrel, or because of glycoprotein (GP)IIbIIIa deficiency, TRALI still developed but no lung hemorrhages were observed. In contrast, when GPVI was immunodepleted, TRALI still occurred, but was occasionally accompanied by hemorrhages. Conclusions Platelets are dispensable for the initiation and development of MHC I-induced TRALI. Although they do not protect against the disruption of the vascular endothelial cell barrier and the subsequent plasma leakage and edema formation, platelets are essential to prevent more serious damage resulting in hemorrhages in alveoli.
Assuntos
Plaquetas/efeitos dos fármacos , Ativação Plaquetária/efeitos dos fármacos , Lesão Pulmonar Aguda Relacionada à Transfusão/sangue , Animais , Anticorpos Monoclonais/imunologia , Aspirina/farmacologia , Transfusão de Sangue , Clopidogrel , Toxina Diftérica , Edema/patologia , Hemorragia/tratamento farmacológico , Antígenos de Histocompatibilidade Classe I/imunologia , Pulmão/imunologia , Pulmão/patologia , Masculino , Megacariócitos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Neutrófilos/imunologia , Inibidores da Agregação Plaquetária/farmacologia , Ratos , Síndrome do Desconforto Respiratório/sangue , Transdução de Sinais , Trombocitopenia/tratamento farmacológico , Trombocitopenia/genética , Ticlopidina/análogos & derivados , Ticlopidina/farmacologiaRESUMO
The dynamics of the actin cytoskeleton, largely controlled by the Rho family of small GTPases (Rho, Rac and Cdc42), is critical for the regulation of platelet responses such as shape change, adhesion, spreading and aggregation. Here, we investigated the role of adenosine diphosphate (ADP), a major co-activator of platelets, on the activation of Rac. ADP rapidly activated Rac in a dose-dependent manner and independently of GPIIb/IIIa and phosphoinositide 3-kinase. ADP alone, used as a primary agonist, activated Rac and its effector PAK via its P2Y1 receptor, through a G(q)-dependent pathway and independently of P2Y12. The P2Y12 receptor appeared unable to activate the GTPase per se as also observed for the adenosine triphosphate receptor P2X1. Conversely, secreted ADP strongly potentiated Rac activation induced by FcgammaRIIa clustering or TRAP via its P2Y12 receptor, the target of antithrombotic thienopyridines. Stimulation of the alpha(2A)-adrenergic receptor/G(z) pathway by epinephrine was able to replace the P2Y12/G(i)-mediated pathway to amplify Rac activation by FcgammaRIIa or by the thrombin receptor PAR-1. This co-activation appeared necessary to reach a full stimulation of Rac as well as PAK activation and actin polymerization and was blocked by a G-protein betagamma subunits scavenger peptide.
Assuntos
Plaquetas/metabolismo , Proteínas de Membrana/fisiologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , Receptores Purinérgicos P2/fisiologia , Actinas/metabolismo , Difosfato de Adenosina/farmacologia , Animais , Relação Dose-Resposta a Droga , GTP Fosfo-Hidrolases/metabolismo , Subunidades alfa de Proteínas de Ligação ao GTP/metabolismo , Subunidades alfa Gq-G11 de Proteínas de Ligação ao GTP/metabolismo , Camundongos , Camundongos Knockout , Proteínas Serina-Treonina Quinases/metabolismo , Receptores Purinérgicos P2Y1 , Receptores Purinérgicos P2Y12 , Quinases Ativadas por p21RESUMO
The human P2Y1 purinoceptor has been expressed in Jurkat cells and the effects of HPLC purified nucleotides on calcium movements were measured. The most potent agonist was 2-methylthio-ADP followed by ADP. ATP, Sp-ATPalphaS and beta,gamma-methylene-ATP were competitive antagonists. Suramin and PPADS inhibited the effects of ADP. This pharmacological profile is the same as that of the so-called P2T purinoceptor responsible for platelet aggregation, which has not yet been identified. Using PCR we found the P2Y1 receptor to be present in blood platelets and megakaryoblastic cell lines. These data suggest that the P2Y1 receptor may be the elusive P2T receptor.
Assuntos
Trifosfato de Adenosina/farmacologia , Plaquetas/metabolismo , Megacariócitos/metabolismo , Proteínas de Membrana , Receptores Purinérgicos P2/biossíntese , Receptores Purinérgicos P2/metabolismo , Difosfato de Adenosina/isolamento & purificação , Difosfato de Adenosina/metabolismo , Difosfato de Adenosina/farmacologia , Trifosfato de Adenosina/análogos & derivados , Trifosfato de Adenosina/isolamento & purificação , Trifosfato de Adenosina/metabolismo , Ligação Competitiva , Plaquetas/efeitos dos fármacos , Cálcio/metabolismo , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Humanos , Células Jurkat/efeitos dos fármacos , Células Jurkat/metabolismo , Megacariócitos/efeitos dos fármacos , Reação em Cadeia da Polimerase , Fosfato de Piridoxal/análogos & derivados , Fosfato de Piridoxal/farmacologia , Receptores Purinérgicos P2/efeitos dos fármacos , Receptores Purinérgicos P2Y1 , Receptores Purinérgicos P2Y12 , Suramina/farmacologiaRESUMO
The aim of the present study was to characterize the pharmacological profile of the P2Y(12) receptor for several adenine triphosphate nucleotides in view of their possible roles as partial agonists or true antagonists. Two distinct cellular systems were used: P2Y(1) receptor deficient mouse platelets ( platelets) previously shown to express a native and functional P2Y(12) receptor and 1321 N1 astrocytoma cells stably expressing the human P2Y(12) receptor (1321 N1 P2Y(12)). ADP and its structural analogues inhibited cAMP accumulation in a dose-dependent manner in both platelets and 1321 N1 P2Y(12) cells with a similar rank order of potency, 2 methylthio-ADP (2MeSADP) >>ADP - Adenosine 5'-(betathio) diphosphate (AlphaDPbetaS). Commercial ATP, 2 chloro; ATP (2ClATP) and 2 methylthio-ATP (2MeSATP) also inhibited cAMP accumulation in both cell systems. In contrast, after creatine phosphate (CP)/creatine phosphokinase (CPK) regeneration, adenine triphosphate nucleotides lost their agonistic effect on platelets and behaved as antagonists of ADP (0.5 microm)-induced adenylyl cyclase inhibition with IC(50) of 13.5 +/- 4.8, 838 +/- 610, 1280 +/- 1246 microm for 2MeSATP, ATP and 2ClATP, respectively. In 1321 N1 P2Y(12) cells, CP/CPK regenerated ATP and 2ClATP lost their agonistic effect only when CP/CPK was maintained during the cAMP assay. The stable ATP analogue ATPgammaS antagonized ADPbetaS-induced inhibition of cAMP accumulation in both platelets and 1321 N1 P2Y(12) cells. Thus, ATP and its triphosphate analogues are not agonists but rather antagonists at the P2Y(12) receptor expressed in platelets or transfected cells, provided care is taken to remove diphosphate contaminants and to prevent the generation of diphosphate nucleotide derivatives by cell ectonucleotidases.
Assuntos
Trifosfato de Adenosina/análogos & derivados , Proteínas de Membrana/antagonistas & inibidores , Antagonistas do Receptor Purinérgico P2 , Difosfato de Adenosina/farmacologia , Trifosfato de Adenosina/farmacologia , Inibidores de Adenilil Ciclases , Animais , Astrocitoma/metabolismo , Astrocitoma/patologia , Plaquetas/química , Linhagem Celular Tumoral , Creatina Quinase/fisiologia , Humanos , Proteínas de Membrana/agonistas , Proteínas de Membrana/genética , Camundongos , Camundongos Knockout , Fosfocreatina , Agregação Plaquetária/efeitos dos fármacos , Agonistas do Receptor Purinérgico P2 , Receptores Purinérgicos P2/genética , Receptores Purinérgicos P2Y12 , TransfecçãoRESUMO
In order to investigate the role of the platelet P2Y1 receptor in several aspects of platelet activation and thrombosis, transgenic (TG) mice overexpressing this receptor specifically in the megakaryocytic/platelet lineage were generated using the promoter of the tissue-specific platelet factor 4 gene. Studies of the saturation binding of [33P]2MeSADP in the presence or absence of the selective P2Y1 antagonist MRS2179 indicated that wild-type (WT) mouse platelets bore 150 +/- 31 P2Y1 receptors and TG platelets 276 +/- 34, representing an 84% increase in P2Y1 receptor density. This led to a well defined phenotype of platelet hyper-reactivity in vitro, as shown by increased aggregations in response to adenosine 5'-diphosphate (ADP) and low concentration of collagen in TG as compared with WT platelets. Moreover, overexpression of the P2Y1 receptor enabled ADP to induce granule secretion, unlike in WT platelets, which suggests that the level of P2Y1 expression is critical for this event. Our results further suggest that the weak responses of normal platelets to ADP are due to a limited number of P2Y1 receptors rather than to activation of a specific transduction pathway. TG mice displayed a shortened bleeding time and an increased sensitivity to in vivo platelet aggregation induced by infusion of a mixture of collagen and epinephrine. Overall, these findings emphasize the importance of the P2Y1 receptor in hemostasis and thrombosis and suggest that variable expression levels of this receptor on platelets might play a role in thrombotic states in human, which remains to be assessed.
Assuntos
Plaquetas/metabolismo , Linhagem da Célula/genética , Ativação Plaquetária/fisiologia , Receptores Purinérgicos P2/biossíntese , Difosfato de Adenosina/análogos & derivados , Difosfato de Adenosina/metabolismo , Difosfato de Adenosina/farmacologia , Animais , Tempo de Sangramento , Cálcio/análise , Cálcio/química , Cálcio/metabolismo , Colágeno/farmacologia , AMP Cíclico/análise , Epinefrina/farmacologia , Expressão Gênica , Masculino , Camundongos , Camundongos Transgênicos , Plasmídeos/genética , Agregação Plaquetária/fisiologia , Fator Plaquetário 4/genética , Regiões Promotoras Genéticas/genética , Ligação Proteica , Antagonistas do Receptor Purinérgico P2 , Receptores Purinérgicos P2/genética , Receptores Purinérgicos P2Y1RESUMO
Human platelets are thought to possess at least two subtypes of purinoceptor, one of which, coupled to G-proteins, could be the P2Y1 receptor (Leon et al. 1997). However, it has been suggested that the unique rapid calcium influx induced by ADP in platelets could involve P2X1 ionotropic receptors (MacKenzie et al. 1996) and the aim of this study was thus to investigate the presence of P2X purinoceptors in platelets and megakaryoblastic cells. Using PCR experiments, we found P2X1 mRNA to be present in human platelets and megakaryoblastic cell lines. In platelets, the selective P2X1 agonist alphabetaMeATP induced a rise in intracellular calcium only in the presence of external calcium and this effect was antagonized by suramin and PPADS. Repeated addition of alphabetaMeATP desensitized the P2X1 purinoceptor but only slightly affected the ADP response, while no calcium response to alphabetaMeATP was observed in megakaryoblastic cells. These results support the existence of functional P2X1 purinoceptors on human platelets and the presence of P2X1 transcripts in megakaryoblastic cell lines.
Assuntos
Plaquetas/química , Megacariócitos/química , Megacariócitos/citologia , Receptores Purinérgicos P2/sangue , Trifosfato de Adenosina/análogos & derivados , Trifosfato de Adenosina/farmacologia , Plaquetas/efeitos dos fármacos , Linhagem Celular , Clonagem Molecular , Humanos , RNA Mensageiro/análise , Receptores Purinérgicos P2/efeitos dos fármacos , Receptores Purinérgicos P2/genéticaRESUMO
The relative contributions of the P2Y1 and P2YT receptors to the morphological changes induced in platelets by ADP or ADP-releasing agonists were assessed using two P2 antagonists, A2P5P and AR-C67085, selective for P2Y1 and P2YT, respectively. The P2Y1 receptor was found to be involved in i) the centralization of secretory granules elicited by ADP, ii) the formation of filopodia induced by released ADP in weakly activated platelets and iii) actin polymerization and the cytoskeletal translocation of cdc42, rac1 and rhoA, in an integrin alphaIIbbeta3 dependent manner, in ADP-stimulated platelets. In contrast, the P2YT receptor was shown i) to be essential for the formation of stable macroaggregates, ii) to enhance actin polymerization and the cytoskeletal translocation of small GTPases, probably through amplification of platelet aggregation, and iii) not to be involved in the early steps of platelet activation since its blockade did not affect the cytoskeletal translocation of rhoA.
Assuntos
Adenosina Difosfato Ribose/análogos & derivados , Adenosina Difosfato Ribose/farmacologia , Monofosfato de Adenosina/análogos & derivados , Monofosfato de Adenosina/farmacologia , Plaquetas/ultraestrutura , Proteínas de Membrana , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/fisiologia , Receptores Purinérgicos P2/fisiologia , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacologia , Actinas/análise , Difosfato de Adenosina/farmacologia , Plaquetas/efeitos dos fármacos , Sinalização do Cálcio/efeitos dos fármacos , Tamanho Celular , Citoesqueleto/efeitos dos fármacos , Citoesqueleto/ultraestrutura , Proteínas de Ligação ao GTP/metabolismo , Humanos , Microscopia Eletrônica , Agregação Plaquetária/efeitos dos fármacos , Receptores Purinérgicos P2/efeitos dos fármacos , Receptores Purinérgicos P2Y1 , Receptores Purinérgicos P2Y12 , Trombina/farmacologia , Proteína cdc42 de Ligação ao GTP/metabolismo , Proteínas rac1 de Ligação ao GTP/metabolismo , Proteína rhoA de Ligação ao GTP/metabolismoRESUMO
Platelets activated by ADP become refractory to restimulation, but the mechanism of this process is not well understood. A normal platelet response to ADP requires coactivation of the P2Y(1) receptor responsible for shape change and the P2cyc receptor, responsible for completion and amplification of the response. The aim of the present study was to characterize the desensitization of platelets to ADP and to determine whether or not these two receptors are desensitized simultaneously through identical pathways when platelets become refractory to ADP. It was found that full inhibition of platelet aggregation in response to restimulation by ADP required the presence of ADP in the medium or use of a high concentration (1 mM) of its non-hydrolysable analogue ADPbetaS. Platelets incubated for 1 h at 37 degrees C with 1 mM ADPbetaS and resuspended in Tyrode's buffer containing apyrase displayed a stable refractory state characterized by the inability to aggregate or change shape in response to ADP. ADPbetaS treated platelets loaded with fura-2/AM showed complete blockade of the calcium signal in response to ADP, whereas the capacity of ADP to inhibit PGE1 stimulated cAMP accumulation in these platelets was only diminished. Consequently, serotonin was able to promote ADP induced aggregation through activation of the Gq coupled 5HT(2A) receptor while adrenaline had no such effect. These results suggested that the refractory state of ADPbetaS treated platelets was entirely due to desensitization of the P2Y(1) receptor, the P2cyc receptor remaining functional. Binding studies were performed to determine whether the P2Y(1) and/or P2cyc binding sites were modified in refractory platelets. Using selective P2Y(1) and P2cyc antagonists (A3P5P and AR-C66096 respectively), we could demonstrate that the decrease in [33P]2MeSADP binding sites on refractory platelets corresponded to disappearance of the P2Y(1) sites with no change in the number of P2cyc sites, suggesting internalization of the P2Y(1) receptor. This was confirmed by flow cytometric analysis of Jurkat cells expressing an epitope-tagged P2Y(1) receptor, where ADPbetaS treatment resulted in complete loss of the receptor from the cell surface. We conclude that the P2Y(1) and P2cyc receptors are differently regulated during platelet activation.
Assuntos
Difosfato de Adenosina/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Sítios de Ligação , Ligação Competitiva , Plaquetas/metabolismo , Plaquetas/fisiologia , Sinalização do Cálcio/efeitos dos fármacos , Relação Dose-Resposta a Droga , Regulação para Baixo , Citometria de Fluxo , Corantes Fluorescentes , Fura-2 , Humanos , Células Jurkat , Agregação Plaquetária/fisiologia , Receptores Purinérgicos P2/metabolismo , Receptores Purinérgicos P2/fisiologia , Receptores Purinérgicos P2Y1 , Proteínas Recombinantes/metabolismo , Fatores de Tempo , TransfecçãoRESUMO
ADP is a key stimulus inducing platelet shape change and aggregation, a rise in internal calcium and inhibition of adenylyl cyclase. These signaling pathways are thought to be activated by three independent receptors, but to date only the P2Y1 receptor responsible for calcium mobilization and the ionotropic P2X1 receptor have been identified. We report here the characteristics of the P2Y1 receptor in a patient presenting a selective deficiency of ADP-induced aggregation. Cloning of the P2Y1 gene revealed that the patient's DNA and mRNA were normal. Pharmacological studies showed that the P2Y1 receptor was expressed and functional in patient's platelets. Hence, the P2Y, receptor is not the cause of the impaired ADP-induced platelet aggregation in this patient. The P2X1 mRNA was also found to be present and normal. These findings add evidence to previous observations suggesting that a third P2 receptor coupled to adenylyl cyclase may be involved in ADP-induced platelet aggregation.
Assuntos
Adenilil Ciclases/metabolismo , Transtornos da Coagulação Sanguínea/genética , Agregação Plaquetária , Receptores Purinérgicos P2/genética , Difosfato de Adenosina/metabolismo , Difosfato de Adenosina/farmacologia , Sequência de Bases , Transtornos da Coagulação Sanguínea/sangue , Transtornos da Coagulação Sanguínea/fisiopatologia , Clonagem Molecular , Humanos , Dados de Sequência Molecular , Agregação Plaquetária/efeitos dos fármacos , Receptores Purinérgicos P2/metabolismo , Receptores Purinérgicos P2Y1RESUMO
BACKGROUND: As well known from former manned spaceflight experiments (German D2-Mission/German D1-Mission 1985/German-Russian MIR-Mission 1 992/German-D2-Mission 1993), fluid shift after entry into microgravity leads to a rapid increase in pressure and volume within the upper compartments of the human body. This has been proven by precise measurements with automatic selftonometers for intraocular pressure. HYPOTHESIS: There is little doubt, that a very similar--even more, marked--increase of intracranial pressure happens soon after entry into microgravity. This may be the cause for some of the reported hormonal and even neurological changes in metabolism. There is no non-invasive method to assess these important increases in pressure. METHODS: Ophthalmodynamometry in general allows for rather precise estimation of intracranial BP, but so far the method was too complicated for routine application, specifically in spaceflight conditions. Therefore, using the microprocessor controlled technology of our automatic selftonometer we have designed a very precise automatic instrument which can be applied by the astronaut/kosmonaut. The measurement takes only a few seconds. CONCLUSIONS: This easily applied, non-invasive method would allow for completely new insights into these important changes and explain some of the clinical consequences noted so far.
Assuntos
Diagnóstico por Computador/métodos , Hipertensão Intracraniana/diagnóstico , Hipertensão Intracraniana/etiologia , Oftalmodinamometria/métodos , Teste da Mesa Inclinada/efeitos adversos , Tonometria Ocular/métodos , Simulação de Ausência de Peso/efeitos adversos , Astronautas , Diagnóstico por Computador/instrumentação , Desenho de Equipamento , Alemanha , Humanos , Microcomputadores , Oftalmodinamometria/instrumentação , Reprodutibilidade dos Testes , Tonometria Ocular/instrumentaçãoRESUMO
The treatment of acute coronary syndromes has been considerably improved in recent years with the introduction of highly efficient antiplatelet drugs. However, there are still significant limitations: the recurrence of adverse vascular events remains a problem, and the improvement in efficacy is counterbalanced by an increased risk of bleeding, which is of particular importance in patients at risk of stroke. One of the most attractive targets for the development of new molecules with potential antithrombotic activity is platelet glycoprotein (GP)VI, because its blockade appears to ideally combine efficacy and safety. This review summarizes current knowledge on GPVI regarding its structure, its function, and its role in physiologic hemostasis and thrombosis. Strategies for inhibiting GPVI are presented, and evidence of the antithrombotic efficacy and safety of GPVI antagonists is provided.